Analytical Data
-
Gene name
BRD3
- Application
-
Alternative Names
KIAA0043; RING3L
-
Species
Human
-
Source
E. coli
-
Tag
His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q15059-1
-
Expression Region
P29-V145
-
Protein Length
Partial
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BRD3 is a member of the Bromodomain and Extra-Terminal (BET) family of proteins, which are known for their role in recognizing acetylated lysines on histones and non-histone proteins, thus influencing gene expression and chromatin dynamics. Research on BRD3 has gained significant attention due to its involvement in various biological processes, including cellular signaling, inflammation, and the regulation of oncogenes. Notably, BRD3 has been implicated in several cancers, making it a potential target for therapeutic intervention. The study of recombinant BRD3 protein, therefore, aims to elucidate its structural properties and functional mechanisms, enhancing our understanding of its role in gene regulation and tumorigenesis. By producing and analyzing recombinant BRD3, researchers can investigate its interactions with acetylated proteins, assess its impact on transcriptional activity, and evaluate its potential as a drug target in cancer therapy. The insights garnered from these studies could pave the way for the development of novel therapeutic strategies, highlighting the importance of BRD3 in both basic research and clinical applications.
